Viracta Therapeutics, Inc. (NASDAQ:VIRX) Short Interest Up 89.9% in December

Viracta Therapeutics, Inc. (NASDAQ:VIRX) was the recipient of a significant increase in short interest in the month of December. As of December 15th, there was short interest totalling 3,000,000 shares, an increase of 89.9% from the November 30th total of 1,580,000 shares. Currently, 10.7% of the shares of the company are sold short. Based on an average trading volume of 2,140,000 shares, the short-interest ratio is presently 1.4 days.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on VIRX. Rodman & Renshaw restated a “neutral” rating and issued a $0.25 price target (down from $3.50) on shares of Viracta Therapeutics in a research report on Friday. Royal Bank of Canada dropped their price objective on shares of Viracta Therapeutics from $4.00 to $2.00 and set an “outperform” rating for the company in a report on Thursday, November 14th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $4.05.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Viracta Therapeutics stock. Stonepine Capital Management LLC bought a new stake in Viracta Therapeutics, Inc. (NASDAQ:VIRX) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 500,000 shares of the company’s stock, valued at approximately $116,000. Stonepine Capital Management LLC owned 1.27% of Viracta Therapeutics as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 31.37% of the company’s stock.

Viracta Therapeutics Stock Down 32.5 %

Viracta Therapeutics stock traded down $0.08 during trading on Friday, reaching $0.16. The stock had a trading volume of 9,373,380 shares, compared to its average volume of 808,326. Viracta Therapeutics has a 52-week low of $0.13 and a 52-week high of $1.31. The stock has a market cap of $6.36 million, a PE ratio of -0.15 and a beta of 0.67. The business has a 50 day moving average price of $0.19 and a 200 day moving average price of $0.31.

Viracta Therapeutics Company Profile

Viracta Therapeutics, Inc, a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir.